Could a malaria drug treat cervical Pre-Cancer?
NCT ID NCT04098744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether artesunate, a drug originally used for malaria, can reverse cervical pre-cancer (CIN2/3) when given as a vaginal insert. About 78 women with high-grade cervical lesions will receive either artesunate or a placebo for three 5-day cycles. The main goal is to see if the lesions shrink or disappear by week 17, potentially offering a non-surgical treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
artesunate vaginal insert
What this could lead to
If it works, this could provide a non-surgical treatment for cervical pre-cancer, potentially reducing the need for procedures like LEEP.
What could go wrong
This is a small, early-phase trial with only 78 participants. It may not show enough benefit over placebo, and the treatment is still experimental with unknown long-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Fairview Hospital
RECRUITINGCleveland, Ohio, 44111, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Florida Gynecologic Oncology
RECRUITINGFort Myers, Florida, 33905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Hillcrest Hospital
RECRUITINGMayfield Heights, Ohio, 44124, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
The Harris Health System (L.B.J Hospital)
RECRUITINGHouston, Texas, 77026, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas, M.D. Anderson
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact